<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care</journal-id><journal-id journal-id-type="iso-abbrev">Crit Care</journal-id><journal-title-group><journal-title>Critical Care</journal-title></journal-title-group><issn pub-type="ppub">1364-8535</issn><issn pub-type="epub">1466-609X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3643068</article-id><article-id pub-id-type="publisher-id">cc12000</article-id><article-id pub-id-type="doi">10.1186/cc12000</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>A multicenter randomized controlled study of an extracorporeal cytokine hemoadsorption device in septic patients</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Sch&#x000e4;dler</surname><given-names>D</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Porzelius</surname><given-names>C</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>J&#x000f6;rres</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Marx</surname><given-names>G</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Meier-Hellmann</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Putensen</surname><given-names>C</given-names></name><xref ref-type="aff" rid="I6">6</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Quintel</surname><given-names>M</given-names></name><xref ref-type="aff" rid="I7">7</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Spies</surname><given-names>C</given-names></name><xref ref-type="aff" rid="I8">8</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Engel</surname><given-names>C</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A10"><name><surname>Weiler</surname><given-names>N</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A11"><name><surname>Kuhlmann</surname><given-names>M</given-names></name><xref ref-type="aff" rid="I9">9</xref></contrib></contrib-group><aff id="I1"><label>1</label>University Medical Center Schleswig-Holstein, Campus Kiel, Germany</aff><aff id="I2"><label>2</label>University of Leipzig, Germany</aff><aff id="I3"><label>3</label>Charit&#x000e9; University Hospital Campus Virchow-Klinikum, Berlin, Germany</aff><aff id="I4"><label>4</label>RWTH University Hospital Aachen, Germany</aff><aff id="I5"><label>5</label>HELIOS Klinikum, Erfurt, Germany</aff><aff id="I6"><label>6</label>University of Bonn, Germany</aff><aff id="I7"><label>7</label>University Hospital G&#x000f6;ttingen, Germany</aff><aff id="I8"><label>8</label>Campus Charit&#x000e9; Mitte and Campus Charit&#x000e9; Virchow-Klinikum, Charit&#x000e9;-University Medicine Berlin, Germany</aff><aff id="I9"><label>9</label>Vivantes Klinikum im Friedrichshain, Berlin, Germany</aff><pub-date pub-type="ppub"><year>2013</year></pub-date><pub-date pub-type="epub"><day>19</day><month>3</month><year>2013</year></pub-date><volume>17</volume><issue>Suppl 2</issue><supplement><named-content content-type="supplement-title">33rd International Symposium on Intensive Care and Emergency Medicine</named-content><named-content content-type="supplement-sponsor">Publication of this supplement was supported by ISICEM</named-content></supplement><fpage>P62</fpage><lpage>P62</lpage><permissions><copyright-statement>Copyright &#x000a9; 2013 Sch&#x000e4;dler et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Sch&#x000e4;dler et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://ccforum.com/content/17/S2/P62"/><conference><conf-date>19-22 March 2013</conf-date><conf-name>33rd International Symposium on Intensive Care and Emergency Medicine</conf-name><conf-loc>Brussels, Belgium</conf-loc></conference></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>A novel sorbent hemoadsorption device for cytokine removal (CytoSorbents, USA) was developed and successfully tested in animal models of sepsis. The experience in the clinical setting is still limited to case reports. In this first clinical trial, we tested the hypothesis that treatment with sorbent hemoadsorption could safely and effectively reduce cytokines in septic patients with acute lung injury (ALI).</p></sec><sec sec-type="methods"><title>Methods</title><p>Ventilated patients fulfilling the criteria for severe sepsis and ALI were enrolled in this multicenter randomized, controlled, open-label study comparing standard of care with or without hemoperfusion treatment. Primary endpoints were safety and IL-6 reduction. Treated patients underwent hemoperfusion at flow rates of ~200 to 3003ml/ minute for 6 hours per day for 7 consecutive days. The overall mean reduction in individual plasma cytokines for the control and treatment groups during the treatment period was calculated using a generalized linear model.</p></sec><sec sec-type="results"><title>Results</title><p>Forty-three patients (18 treated, 25 control) completed the study and were further analyzed. Incidence of organ dysfunction at enrollment (treatment vs. control) was: septic shock (94% vs. 100%, <italic>P </italic>= 0.42), acute respiratory distress syndrome (67% vs. 56%, <italic>P </italic>= 0.33), and renal failure (39% vs. 24%, <italic>P </italic>= 0.54). During 115 treatments no serious device-related adverse events occurred. On average, there were no changes in hematology and other blood parameters except for a modest reduction in platelet count (&#x0003c;10%) and albumin (&#x0003c;5%) with treatment. Hemoperfusion decreased IL-6 blood concentration significantly (-49.1%, <italic>P </italic>= 0.01), with similar reductions of MCP-1 (-49.5%, <italic>P </italic>= 0.002), IL-1ra (-36.5%, <italic>P </italic>= 0.001), and IL-8 (-30.2%, <italic>P </italic>= 0.002). The 28-day mortality (28% vs. 24% control, <italic>P </italic>= 0.84) and 60-day mortality (39% vs. 32% control, <italic>P </italic>= 0.75) did not differ significantly between the two studied groups.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>In this first clinical study of a novel sorbent hemoadsorption device in patients with severe sepsis and ALI, the device appeared to be safe and decreased the blood concentration of several cytokines. Further research is needed to study the effect of the device on the clinical outcome of septic patients.</p></sec></body></article>